< Back

Compounded Tirzepatide

MED-000013

Compounded tirzepatide is a non-FDA-approved version of tirzepatide prepared by compounding pharmacies. Its legal status has shifted repeatedly since 2024 and, unlike semaglutide, some reports indicate tirzepatide returned to a shortage-adjacent status in 2025 — making current availability genuinely unsettled and worth verifying directly with the FDA before assuming either way.

Medication Overview

Generic Name:

Medication Class:

Manufacturer:

Route:

Dosing Frequency:

Tirzepatide

Compound

Compounding Pharmacy

Injection

Variable

Status:

Draft

Medication Summary

Aliases

Compounded Tirzepatide

Search Keywords

compounded tirzepatide

Medication Uses

Part of the DietApp.com GLP-1 Medication Database, a comprehensive, regularly reviewed reference covering every GLP-1-class medication.

Compounded tirzepatide refers to versions of tirzepatide prepared by a compounding pharmacy rather than manufactured by Eli Lilly (maker of Mounjaro® and Zepbound®). Like compounded semaglutide, these products are not FDA-approved and don't undergo premarket review for safety, effectiveness, or manufacturing quality.

Current legal status (2026): The FDA declared the original tirzepatide shortage resolved in December 2024, which triggered wind-down deadlines for compounders. However, reporting on tirzepatide's status through 2026 is genuinely mixed — some sources report it remained off the shortage list with only narrow 503A "documented clinical need" exceptions available (mirroring semaglutide), while others report tirzepatide returned to shortage status at some point in 2025, which would restore broader compounding access including 503B facilities. On April 30, 2026, the FDA proposed removing tirzepatide from the 503B bulks list regardless of shortage status. Given this inconsistency across sources, check the FDA's official drug shortage database directly for tirzepatide's current status before assuming either way.

Dosage

Compounded tirzepatide dosing varies by compounding pharmacy and is not standardized or FDA-reviewed the way Mounjaro or Zepbound dosing is.

Administration

Administration varies by product and compounding pharmacy. Packaging, concentration labeling, and delivery devices are not standardized across suppliers the way they are for FDA-approved tirzepatide products.

Benefits

The active ingredient, when accurately compounded, is chemically the same as FDA-approved tirzepatide. However, compounded products aren't independently tested by the FDA for potency or purity before reaching patients.

Side Effects

Reported side effects are generally consistent with FDA-approved tirzepatide (nausea, vomiting, diarrhea, injection-site reactions), but the FDA has also received over 320 adverse event reports specifically tied to compounded tirzepatide, including dosing errors from multidose vials.

Warnings

Compounded tirzepatide has not been reviewed by the FDA for safety, effectiveness, or manufacturing quality. A 2026 laboratory study identified a previously undocumented tirzepatide-B12 compound in some mass-compounded tirzepatide-B12 products — a substance not present in FDA-approved tirzepatide, with unknown safety implications. Documented risks also include dosing errors, inconsistent purity between batches and suppliers, and counterfeit products from unlicensed sellers. Eli Lilly has pursued legal action against clinics misrepresenting compounded products as Mounjaro or Zepbound.

Drug Interactions

Interaction risks are expected to be similar to FDA-approved tirzepatide, but compounded formulations that include added ingredients (such as B-vitamins marketed as "personalized" blends) cannot be assumed to carry the same safety and interaction profile as the approved product.

Storage

Storage requirements vary by compounding pharmacy and are not standardized or FDA-verified. Follow your specific pharmacy's instructions exactly.

References

FDA: Compounded GLP-1 Products enforcement updates (2025-2026)
Portrait Care: 2026 FDA Rules and News for Compounded Tirzepatide
GLP-1 After Denial: Is Compounded Semaglutide Still Legal? (2026 Update)

Last medically reviewed and updated: July 11, 2026.

Track Your Progress

Whatever form of tirzepatide you're using, DietApp.com helps you track your dose, nutrition, weight, and symptoms in one place — useful context to bring to your provider regardless of your medication source.

Download DietApp.com

Related Resources

Tirzepatide Medication Guide
Mounjaro Medication Guide
Zepbound Medication Guide
GLP-1 Medication Library
Medication Safety Information

Is Compounded Tirzepatide Legal? 2026 Status
Compounded vs. Brand-Name GLP-1s: What's the Real Difference?
What Is Tirzepatide?
Frequently Asked Questions About GLP-1 Therapy

More From DietApp.com

Explore the full GLP-1 Tracker knowledge base on DietApp.com

Explore DietApp.com Tools

BMI Calculator — Get an instant estimate and see what it does (and doesn't) tell you about your health
GLP-1 Dose & Injection Tracker — Log your dose automatically
AI Food Recognition — Snap a photo of your meal for instant protein, fiber, and calorie tracking
Protein & Hydration Dashboard — See your daily totals at a glance
Symptom & Side Effect Log — Track patterns over time to bring to your next appointment
Download DietApp.com — Start tracking your GLP-1 journey today

About DietApp.com

DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. This page is for general informational purposes and is not medical, legal, or purchasing advice. The information on DietApp.com should not replace professional medical advice, diagnosis, or treatment.